Clinical Trials Browser

Phase 2 × Carcinoma, Neuroendocrine × Dermatologic × Clear all

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT06683846 2025-08-24

Ivonescimab in the Treatment of Multiple Advanced Tumors

Phase 2 Recruiting

400 enrolled

CNSDermatologicEndocrineGenitourinarySarcoma

Urachal cancer, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Paget Disease, Extramammary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rhabdomyosarcoma, Sarcoma, Angiomyolipoma, Carcinoma, Neuroendocrine, Perivascular Epithelioid Cell Neoplasms

NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Phase 2 Withdrawn

DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

NCT00004922 2013-06-19

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

Phase 2 Completed

DermatologicEndocrine

Neoplasms, Unknown Primary, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Clinical Trials

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Ivonescimab in the Treatment of Multiple Advanced Tumors

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors